Videos

Samantha Pettigrew, MD, reviews HI-PEITHO, PRAGUE-26, and PEERLESS and how they shape intervention choices in intermediate-risk PE at CHEST 2026.

Anjali Vaidya, MD, explains why echocardiography should inform right heart catheterization interpretation in pulmonary hypertension at CHEST 2026.

Omid Pourshahid, MD, MPH, discusses Medicare coverage for virtual pulmonary rehab and a matched-care pathway for center-based, hybrid, or virtual programs.

David Rubin, MD, discusses GALAXI and GRAVITI data showing guselkumab improved non-passable intestinal stenosis in Crohn’s disease through 2 years.

Yoseph Dalia, MD, discusses diagnosing and treating pseudofolliculitis barbae, its occupational impact, and barriers to care in skin of color.

Catch up on any data and key clinician perspectives presented at the Heart Failure Society of America Annual Scientific Meeting 2026.

At CHEST 2026, Pourshahid argued for matching patients to center-based, hybrid, or virtual pulmonary rehab based on a structured assessment.

Mathew Maurer, MD, discusses the results of the phase 3 REVEAL study, which highlighted this novel scanning technology’s capacity for identifying amyloidosis early.

Jennifer Vittorio, MD, discusses EXPAND pruritus and serum bile acid results, the ItchRO(Obs) endpoint, and implications for biliary atresia.

Quin Denfeld, PhD, discusses her findings from the BIOMES-HF study, indicating worsening symptoms in patients with HF over time.

Jennifer Vittorio, MD, of NYU Langone, explains how itch presents from infancy to adolescence and why off-label options fell short.

Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss a major breakthrough with the Twiist insulin pump and the recent ADA/EASD T2D guidelines.

David Cotter, MD, PhD, explains how remibrutinib's approval for symptomatic dermographism changes treatment sequencing in chronic urticaria.

Ronnie Fass, MD, discusses phase 3 TRIUMpH-NERD data showing tegoprazan increased heartburn-free and regurgitation-free days vs placebo in NERD.

Tina Bhutani, MD, MAS, discusses 3-year VALUE data on risankizumab in high-impact psoriasis and why biologics belong earlier in moderate disease.

David Cotter, MD, PhD, unpacks BE BOLD's bimekizumab vs risankizumab ACR50 results and what they mean for dermatologists treating PsA.

Nicholas Shaheen, MD, MPH, discusses DETECT-ME data showing a capsule-sponge methylation test detected Barrett’s esophagus with 90% sensitivity.

Mirikizumab LUCENT data from UEG Week 2026: 27.7% reached comprehensive disease control at week 52, with high IBDQ remission rates.

GI health care use still fell among patients who had already tried another IBS-C drug, per a real world ACG 2026 analysis.

Victoria P. Werth, MD, and François Chasset, MD, PhD, discuss 52-week AMETHYST Part A data showing litifilimab responses continued to rise.

James Januzzi, MD, discusses the recently released guideline update and how it should change clinicians’ priorities in addressing and preempting HFpEF.

A real world analysis of 470 patients presented at ACG 2026 found median GI visits fell from 4.5 to 3.0 in the year after initiation

James Januzzi, MD, discusses his post-hoc analysis of the ATTRibute-CM study, revealing a potential predictive ratio between these 2 measurements.

Aasma Shaukat, MD, MPH, discusses an updated SimpleScreen CRC blood test with 18.2% sensitivity for advanced precancerous lesions, up from 13.7%.

Ramesh outlines early food introduction, oral immunotherapy, omalizumab, and genetic insights shaping how allergists treat allergic disease.

Evan Dellon, MD, discusses phase 3 CROSSING data in which tezepelumab improved histology, dysphagia, and endoscopic findings vs placebo in EoE.

Martin Maron, MD, discusses the results of his responder analysis of the trial, presented at HFSA 2026, and the implications for aficamten’s path towards approval.

Montefiore allergist outlines updated guidance on home monitoring after epinephrine and why immunotherapy remains underused in allergic rhinitis.